MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Journal of Immune Based Therapies and Vaccines' source. Fri, 30 Dec 2011 19:16:33 +0100 http://www.medworm.com/index.php?rid=5382855&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F9%2F1%2F8 Mycobacterium avium subsp. paratuberculosis (MAP) infection causes in ruminants a regional chronic enteritis that is increasingly being recognized as a significant problem affecting animal health, farming and the food industry due to the high prevalence of the disease and to recent research data strengthening the link between the pathogen and human inflammatory bowel disease (IBD). Control of the infection through hygiene-management measures and test and culling of positive animals has to date not produced the expected results and thus a new focus on vaccination against this pathogen is necessary. This review summarizes all vaccination studies of cattle, sheep or goats reporting production, epidemiological or pathogenetic effects of vaccination published before January 2010 and that provid... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=5382855 Mon, 31 Oct 2011 04:00:00 +0100 5382855 http://www.medworm.com/index.php?rid=5346526&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F9%2F1%2F7 The prognosis of patients with advanced non small cell lung (NSCLC] cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF] conjugated to a carrier protein, P64K from Neisseria Meningitides. The vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction. CimaVax-EGF has been evaluated so far in more than 1000 advanced NSCLC patients, as second line therapy. Two separate studies were compared to assess the impact of high dose vaccination at multiple anatomic sites in terms of immunogenicity, safety and preliminary efficacy ... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=5346526 Mon, 24 Oct 2011 04:00:00 +0100 5346526 http://www.medworm.com/index.php?rid=5323423&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F9%2F1%2F6 Conclusions: These results indicate that immunization of mice with P. berghei p52-GAP results in immune responses that are comparable to those induced by RAS or GAP lacking expression of UIS3 or UIS4, with an important role implicated for intrahepatic effector memory CD8+ T cells. The knowledge of the mediators of protective immunity after immunization with different GAP is important for the further development of vaccines consisting of genetically attenuated sporozoites. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=5323423 Mon, 17 Oct 2011 04:00:00 +0100 5323423 http://www.medworm.com/index.php?rid=5078301&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F9%2F1%2F5 ${item.shortDescription} (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=5078301 Thu, 28 Jul 2011 23:00:00 +0100 5078301 http://www.medworm.com/index.php?rid=4969536&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F9%2F1%2F4 Conclusions: We demonstrated in this study that the new combination approach using immunotherapy and concurrent chemotherapy should offer several improvements over the existing regimens to treat tuberculosis. The therapeutic effect is associated not only with initiating a Th1 response but also with switching the insufficient Th2 immune status to the more protective Th1 response. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=4969536 Sat, 25 Jun 2011 23:00:00 +0100 4969536 http://www.medworm.com/index.php?rid=4362037&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F9%2F1%2F2 Conclusions: The present study demonstrates in a pre-clinical vaccine model, that prior oral immunization with an empty Lm vector does not diminish immunogenicity to Lm-expressed HIV genes. This work underscores the need for the continued development of attenuated Lm as an orally deliverable vaccine. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=4362037 Tue, 18 Jan 2011 00:00:00 +0100 4362037 http://www.medworm.com/index.php?rid=4362036&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F9%2F1%2F3 Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases to investigate the safety and efficacy of an oral immune adjunct (V5). The immunotherapy (N=24) and placebo (N=10) arms received once-daily tablet of V5 or placebo for one month in addition to conventional anti-TB therapy (ATT) administered under directly observed therapy (DOT). The enlarged liver, total bilirubin, erythrocyte sedimentation rate, lymphocyte and leukocyte counts improved significantly in V5 recipients (P=0.002; 0.03; 8.3E-007; 2.8E-005; and 0.002) but remained statistically unchanged in the placebo group (P=0.68; 0.96; 0.61; 0.91; and 0.43 respectively).The changes in hemoglobin and ALT levels in both treatment arms... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=4362036 Tue, 18 Jan 2011 00:00:00 +0100 4362036 http://www.medworm.com/index.php?rid=4338745&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F9%2F1%2F1 This report does not cover all presentations, but aims to highlight selected points of interest, particularly relating to possible limitations and potential approaches to improvement of DC therapies specifically, and also immunotherapeutic interventions in general terms. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=4338745 Wed, 12 Jan 2011 00:00:00 +0100 4338745 http://www.medworm.com/index.php?rid=4278115&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F9 Conclusion: We have generated high-affinity SEB-specific antibodies capable of neutralizing SEB in vitro as well as in vivo in a mouse model. Taken together, these results suggest that our antibodies hold the potential as passive immunotherapies for both prophylactic and therapeutic countermeasures of SEB exposure. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=4278115 Tue, 21 Dec 2010 00:00:00 +0100 4278115 http://www.medworm.com/index.php?rid=4197579&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F8 Dendritic cells (DCs) play a key role in innate and adaptive immunity but the access to sufficient amount of DCs for basic and translational research has been limited.We established a novel ex vivo system to develop and expand DCs from hematopoietic stem/progenitor cells (HPCs). Both human and mouse HPCs were expanded first in feeder culture supplemented with c-Kit ligand (KL, stem cell factor, steel factor or CD117 ligand), Flt3 ligand (fms-like tyrosine kinase 3, Flt3L, FL), thrombopoietin (TPO), IL-3, IL-6, and basic fibroblast growth factor (bFGF), and then in a second feeder culture ectopically expressing all above growth factors plus GM-CSF and IL-15.In the dual culture system, CD34+ HPCs differentiated toward DC progenitors (DCPs), which expanded more than five orders of magnitude. ... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=4197579 Wed, 24 Nov 2010 00:00:00 +0100 4197579 http://www.medworm.com/index.php?rid=4183756&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F7 In this study, we evaluated the potential of two novel chimaeric HIV-1 Pr55Gag-based VLP constructs - C-terminal fusions with reverse transcriptase and a Tat::Nef fusion protein, designated GagRT and GagTN respectively - to enhance a cellular response in mice when used as boost components in two types of heterologous prime-boost vaccine strategies. A vaccine regimen consisting of a DNA prime and chimaeric HIV-1 VLP boosts in mice induced strong, broad cellular immune responses at an optimum dose of 100 ng VLPs. The enhanced cellular responses induced by the DNA prime-VLP boost were two- to three-fold greater than two DNA vaccinations. Moreover, a mixture of GagRT and GagTN VLPs also boosted antigen-specific CD8+ and CD4+ T-cell responses, while VLP vaccinations only induced predominantly r... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=4183756 Fri, 19 Nov 2010 00:00:00 +0100 4183756 http://www.medworm.com/index.php?rid=4172363&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F6 Conclusions: Engystol(R) and Gripp-Heel(R) inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=4172363 Tue, 16 Nov 2010 00:00:00 +0100 4172363 http://www.medworm.com/index.php?rid=3962590&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F5 Conclusions: These data provide insights into the complex nature of innate immune responses induced following intranasal immunisation within the upper respiratory tract and may help clarify the concepts and provide the tools that are needed to exploit the full potential of mucosal vaccines. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=3962590 Sun, 12 Sep 2010 23:00:00 +0100 3962590 http://www.medworm.com/index.php?rid=3896778&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F4 Conclusions: We conclude that PCEP is a potent and versatile mucosal adjuvant that can be administered in a variety of routes and effectively enhances systemic and local immune responses. Furthermore, intranasal immunization was found to be the best administration route for enhancing IgA titers, providing further evidence for the potential of PCEP as a mucosal adjuvant. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=3896778 Mon, 23 Aug 2010 23:00:00 +0100 3896778 http://www.medworm.com/index.php?rid=3608458&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F3 Conclusion: The repeat BCG stimulation of PBMC obtained from BCG vaccinated individuals shows enhanced immune activation with respect to increased anti-BCG titre, IFN-gamma and ADA activity without concomitant increase in CD4 and CD8 cells. This study provides some basic data in future experiments in animal models with respect to repeat BCG vaccination (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=3608458 Thu, 27 May 2010 23:00:00 +0100 3608458 http://www.medworm.com/index.php?rid=3244983&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F2 Studies have shown that CpG oligodeoxyribonucleotides (ODN) protect mice from various bacterial pathogens, including Burkholderia pseudomallei and Francisella tularensis live vaccine strain (LVS), when administered before parenteral challenge. Given the potential to develop CpG ODN as a pre-treatment for multiple bacterial biological warfare agents, we examined survival, histopathology, and cytokine data from CpG ODN-treated C57BL/6 mice to determine whether previously-reported protection extended to aerosolized B. pseudomallei 1026b and highly virulent F. tularensis Schu S4 infections. We found that, although CpG ODN protected mice from aerosolized B. pseudomallei challenges, the immunostimulant failed to benefit the animals exposed to F. tularensis Schu S4 aerosols. Our results, which co... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=3244983 Fri, 05 Feb 2010 00:00:00 +0100 3244983 http://www.medworm.com/index.php?rid=3236874&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F8%2F1%2F1 Active vaccination can be effective as a post-exposure prophylaxis, but the rapidity of the immune response induced, relative to the incubation time of the pathogen, is critical. We show here that CD40mAb conjugated to antigen induces a more rapid specific antibody response than currently used immunological adjuvants, alum and monophosphoryl lipid A. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=3236874 Thu, 04 Feb 2010 00:00:00 +0100 3236874 http://www.medworm.com/index.php?rid=2883676&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F7%2F1%2F5 Conclusions: This study demonstrates the cross-clade neutralizing activity of a MAb directed against an epitope located in the C2 region of the HIV-1 env and highlights differences in the exposure of antigenic epitopes on the surface of various HIV-1 subtypes. The epitope for this newly identified neutralizing MAb made against a subtype CRF01_AE peptide is particularly exposed in subtype C viral isolates. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=2883676 Sun, 11 Oct 2009 23:00:00 +0100 2883676 http://www.medworm.com/index.php?rid=2794074&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F7%2F1%2F4 Conclusion: The data presented in this study encourages a further investigation in the regulatory potential of the DNA-HSP65 construct. Our findings have important implications for the development of new immune therapy strategies to combat autoimmune diseases. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=2794074 Mon, 14 Sep 2009 23:00:00 +0100 2794074 http://www.medworm.com/index.php?rid=2773160&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F7%2F1%2F3 Experiments almost 20 years ago demonstrated that injections of a sequence of DNA encoding part of a pathogen could stimulate immunity. It was soon realized that "DNA vaccination" had numerous potential advantages over conventional vaccine approaches including inherent safety and a more rapid production time. These and other attributes make DNA vaccines ideal for development against emerging pathogens. Recent advances in optimizing various aspects of DNA vaccination have accelerated this approach from concept to reality in contemporary human trials. Although not yet licensed for human use, several DNA vaccines have now been approved for animal health indications. The rapid manufacturing capabilities of DNA vaccines may be particularly important for emerging infectious diseases including th... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=2773160 Sun, 06 Sep 2009 23:00:00 +0100 2773160 http://www.medworm.com/index.php?rid=2679627&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F7%2F1%2F2 Influenza viruses pose a permanent threat to human populations due to their ability to constantly adapt to impact immunologically susceptible individuals in the forms of epidemic and pandemics through antigenic drifts and antigenic shifts, respectively. Pandemic influenza preparedness is a critical step in responding to future influenza outbreaks. In this regard, responding to the current pandemic and preparing for future ones requires critical planning for the early phases where there is no availability of pandemic vaccine with rapid deployment of medical supplies for personal protection, antivirals, antibiotics and social distancing measures. In addition, it has become clear that responding to the current pandemic or preparing for future ones, nation states need to develop or strengthen... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=2679627 Thu, 06 Aug 2009 23:00:00 +0100 2679627 http://www.medworm.com/index.php?rid=1805569&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F6%2F1%2F5 Conclusion: Our results demonstrated that the physical separation of vaccines both in the syringe and at the site of administration did not adversely affect the biological activity of each component.The vaccination method we describe may be scalable to include a greater number of antigens, while avoiding the physical and chemical incompatibilities encountered by combining multiple vaccines together in one product. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=1805569 Wed, 03 Sep 2008 04:00:00 +0100 1805569 http://www.medworm.com/index.php?rid=1738439&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F6%2F1%2F4 Conclusion: In addition to enhancing humoral responses to vaccination, we describe for the first time that CPG 7909 enhances cellular immunity to vaccine antigen in a typically hyporesponsive population. This adjuvancy may be important in the development of an effective vaccine for which a cellular immune response is required for protection. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=1738439 Tue, 12 Aug 2008 04:00:00 +0100 1738439 http://www.medworm.com/index.php?rid=1506950&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F6%2F1%2F3 Conclusions: The strong immune stimulatory effect of CpG on PBMC isolated from treatment-failed HCV patients suggests possible utility alone or in combination with current HCV antiviral treatment. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=1506950 Mon, 09 Jun 2008 04:00:00 +0100 1506950 http://www.medworm.com/index.php?rid=1438896&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F6%2F1%2F2 Conclusion: Since, HSP-associated peptides are known to mediate tumor rejection; these data suggest that immune-mediated eradication of MM cells could be elicited via a UV-induced HSP process. The finding that the addition of 17-allylamide-17-demethoxygeldanamycin (17AAG, an inhibitor of HSP 90-peptide interactions) resulted in decreased CTL-induced cytotoxicity supported this hypothesis. Our study, therefore, provides the framework for the development of anti-tumor CTL cellular vaccines for treating MM using UV-irradiated tumor cells as immunogens. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=1438896 Mon, 28 Apr 2008 04:00:00 +0100 1438896 http://www.medworm.com/index.php?rid=1366236&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F6%2F1%2F1 Conclusion: Our results indicate that the roller bottle technology can generate similar numbers of mDC from adherent PBMC as traditional static flask methods, but with having to use fewer culture vessels. Thus, this may be a more practical method to generate mDC in large-scale cutting down on the amount of laboratory manipulations, and can save both time and labor costs. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=1366236 Thu, 06 Mar 2008 05:00:00 +0100 1366236 http://www.medworm.com/index.php?rid=1105713&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F12 One needs to think outside of the box, as one of us (Ronald B Luftig) learned from many years as a mathematician, and a biophysicist. In this short Review, the need to focus on producing high levels of neutralizing antibodies (NAbs) to incoming and conformationally altered virus after it has bound to CD4+ cells is essential. Increasing the number of gp120 molecules on the surface of L-2 particles, could allow for an enhanced number of NAbs. The attempt at increasing CD8+ T cell responses in recent vaccine trials has not worked perhaps because it may have allowed HIV to enter into remote sanctuaries. Our approach focuses on increasing NAbs, before high levels of CD8+ T cells are produced. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=1105713 Wed, 19 Dec 2007 05:00:00 +0100 1105713 http://www.medworm.com/index.php?rid=969731&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F11 Conclusions: The protection afforded by these GMP-grade caprine immunotherapeutics post-exposure in the pilot murine model suggests they could be used effectively to treat post-exposure, symptomatic human anthrax patients following a bioterrorism event. These results also indicate that recombinant PA83 coupled to NT-MDP is a potent inducer of neutralizing antibodies and suggest it would be a promising vaccine candidate for anthrax. The ease of production, ease of covalent attachment, and immunostimulatory activity of the NT-MDP indicate it would be a superior adjuvant to alum or other traditional adjuvants in vaccine formulations. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=969731 Mon, 22 Oct 2007 04:00:00 +0100 969731 http://www.medworm.com/index.php?rid=669576&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F8 This study aims at ascertaining the need for a booster at a later age as indicated by in vitro release of IFN-g while evaluating Ag85A as an antigen. Methods: Ninety healthy children who were without any clinical evidence of the disease, 45 with a BCG-scar and the remaining 45 without scar and 25 with tuberculosis were included in the study. The incidence of TB was analyzed in 216 children attending a DOTS clinic during 1996-2005. CD3+, CD4+ and CD8+ cell counts were measured by Flow cytometry. r32kDaBCG (Ag85A-BCG) protein was used to stimulate T cells in in vitro T cell responses and interferon-g (IFN-g) cytokine levels in the supernatants were measured by ELISA. Results: High incidence of TB was observed in age group 13-14 years followed by children in the age group 10-12 years (Chi-squ... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=669576 Thu, 07 Jun 2007 04:00:00 +0100 669576 http://www.medworm.com/index.php?rid=540335&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F6 Conclusions: Induction of HIV-1-specific cell-mediated responses is a major challenge in chronically HIV-1-infected patients even when combining immunisation with IL-2 therapy. An antigen-specific IL-4-associated suppressive response may play a role in attenuating HIV-specific responses. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=540335 Wed, 11 Apr 2007 04:00:00 +0100 540335 http://www.medworm.com/index.php?rid=513769&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F5 Conclusions: IMP321 as an adjuvant to HBsAg was well-tolerated and enhanced T cell response vaccine immunogenicity (i.e. induced both CD4 Th1 and CD8 Tc1 antigen-specific T cells). This latter property has allowed the development of IMP321 as an immunopotentiator for therapeutic vaccines. Trial Registration clinicaltrials.gov Identifier: NCT00354861 (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=513769 Thu, 29 Mar 2007 04:00:00 +0100 513769 http://www.medworm.com/index.php?rid=437563&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F4 Conclusion: The recombinant human gelatin demonstrated similar ability to stabilize the live attenuated VZV (Oka/Merck) in an experimental, refrigerator-stable varicella vaccine when compared to the vaccine preparation formulated with hydrolyzed porcine gelatin used in currently marketed varicella vaccine. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=437563 Fri, 23 Feb 2007 07:00:00 +0100 437563 http://www.medworm.com/index.php?rid=451894&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F4 Conclusion: The recombinant human gelatin demonstrated similar ability to stabilize the live attenuated VZV (Oka/Merck) in an experimental, refrigerator-stable varicella vaccine when compared to the vaccine preparation formulated with hydrolyzed porcine gelatin used in currently marketed varicella vaccine. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=451894 Fri, 23 Feb 2007 05:00:00 +0100 451894 http://www.medworm.com/index.php?rid=437564&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F3 (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=437564 Thu, 22 Feb 2007 07:00:00 +0100 437564 http://www.medworm.com/index.php?rid=451895&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F3 This is a correction article. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=451895 Thu, 22 Feb 2007 05:00:00 +0100 451895 http://www.medworm.com/index.php?rid=411865&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F2 In this study, we sought to determine whether the balance between immunity and immunosuppression could be shifted towards a CD8 anti-CTCL response by lowering the ratio of apoptotic CTCL cells available for DC ingestion. CTCL cell apoptosis was produced by engagement of the TCR by anti-CD3 antibody affixed to magnetic beads. Results: The physical perturbation inherent in passage through a separation column induced monocytes to differentiate into DC, demonstrated by increased expression of class II and CD86 and decreased expression of the monocyte marker CD14. The immature DC internalized and processed apoptotic CTCL cells and could potentially present the tumor-derived peptides in the context of MHC class I and II. As the number of apoptotic cells increased, there was a dose-dependent incr... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=411865 Fri, 09 Feb 2007 07:00:00 +0100 411865 http://www.medworm.com/index.php?rid=386176&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F5%2F1%2F1 Conclusions: CpG-ODN treatment did not induce specific maturation and cytokine expression in foal macrophages and DCs. Nevertheless, adult horse DCs, but not macrophages, increased their expression of IL-12 and IFNa; cytokines upon CpG-ODN stimulation. Importantly, foals presented an age-dependent limitation in the expression of MHC class II in macrophages and DCs, independent of treatment. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=386176 Thu, 25 Jan 2007 07:00:00 +0100 386176 http://www.medworm.com/index.php?rid=298459&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F7 This study explored whether HAART intensification with RemuneTM vaccination before TI can boost HIV-1-specific immunity, leading to improved control of viremia off HAART. Methods: Ten chronically HIV-infected adults were enrolled in this proof of concept study. After a 6-month HAART intensification phase with didanosine, hydroxyurea, granulocyte-macrophage colony-stimulating factor, (GM-CSF), and a first dose of RemuneTM (HIV-1 Immunogen), HAART was discontinued. Patients continued to receive RemuneTM every 3 months until the end of study. HAART was restarted if viral load did not fall below 50,000 copies/ml of plasma within 3 months or if CD4+ counts decreased to (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=298459 Tue, 28 Nov 2006 07:00:00 +0100 298459 http://www.medworm.com/index.php?rid=451896&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F7 This study explored whether HAART intensification with Remune™ vaccination before TI can boost HIV-1-specific immunity, leading to improved control of viremia off HAART. Methods: Ten chronically HIV-infected adults were enrolled in this proof of concept study. After a 6-month HAART intensification phase with didanosine, hydroxyurea, granulocyte-macrophage colony-stimulating factor, (GM-CSF), and a first dose of Remune™ (HIV-1 Immunogen), HAART was discontinued. Patients continued to receive Remune™ every 3 months until the end of study. HAART was restarted if viral load did not fall below 50,000 copies/ml of plasma within 3 months or if CD4+ counts decreased to (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=451896 Tue, 28 Nov 2006 05:00:00 +0100 451896 http://www.medworm.com/index.php?rid=252142&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F5 Conclusion: Our results show that vaccine formulations containing phytol and PHIS-01 as adjuvants confer a robust and protective immunity against both Gram-negative and Gram-positive bacteria without inducing adverse inflammatory cytokine due to IL-6. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=252142 Mon, 23 Oct 2006 06:00:00 +0100 252142 http://www.medworm.com/index.php?rid=175953&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F4 Conclusions: This study demonstrates the immune response to oral immunisation with M. bovis BCG Moreau RDJ in humans. All subjects, including those who did not respond to the skin test at study commencement, were capable of mounting humoral and cellular immune responses to the antigens tested. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=175953 Wed, 06 Sep 2006 06:00:00 +0100 175953 http://www.medworm.com/index.php?rid=451897&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F4 Conclusion: All subjects, including those who did not respond to the skin test at study commencement, were capable of mounting humoral and cellular immune response to the antigens tested. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=451897 Wed, 06 Sep 2006 04:00:00 +0100 451897 http://www.medworm.com/index.php?rid=47554&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F3 Background: Hemodialysis patient are at high risk for hepatitis B virus (HBV) infection. Although preventive vaccination is done routinely, the response to vaccination is low in this patient population. The aim of this study was to evaluate the effect of Levamizol, an enhancer of the immune responsiveness, on different routs of vaccination, i.e., intradermal (ID) versus intramuscular (IM), in stable chronic hemodialysis patients. Material and method: Forty four chronic heamodialyses patient were divided into four equal groups. The first group was received 40 ug HB vaccine intramuscularly. The second group was received 20ug HB vaccine intradermally. The third and the fourth group received 20ug vaccine IM or ID, respectively, in three doses plus oral Levamisole (100mg for12day). After on... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=47554 Tue, 30 May 2006 06:00:00 +0100 47554 http://www.medworm.com/index.php?rid=43951&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F3 Background: Hemodialysis patient are at high risk for hepatitis B virus (HBV) infection. Although preventive vaccination is done routinely, the response to vaccination is low in this patient population. The aim of this study was to evaluate the effect of Levamizol, an enhancer of the immune responsiveness, on different routs of vaccination, i.e., intradermal (ID) versus intramuscular (IM), in stable chronic hemodialysis patients. Material and method: Forty four chronic heamodialyses patient were divided into four equal groups. The first group was received 40 ug HB vaccine intramuscularly. The second group was received 20ug HB vaccine intradermally. The third and the fourth group received 20ug vaccine IM or ID, respectively, in three doses plus oral Levamisole (100mg for12day). After on... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=43951 Tue, 30 May 2006 06:00:00 +0100 43951 http://www.medworm.com/index.php?rid=22514&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F2 The heat shock protein, Hsp70, has been shown to play an important role in tumour immunity. Vaccination with Hsp70-peptide complexes (Hsp70-PCs), isolated from autologous tumour cells, can induce protective immune responses. We have developed a novel method to identify synthetic mimic peptides of Hsp70-PCs and to test their ability to activate T-cells. Peptides (referred to as "recognisers") that bind to Hsp70-PCs from the human breast carcinoma cell line, MDA-MB-231, were identified by bio-panning a random peptide M13 phage display library. Synthetic recogniser peptides were subsequently used as bait in a reverse bio-panning experiment to identify potential Hsp70-PC mimic peptides. The ability of the recogniser and mimic peptides to prime human lymphocyte responses against tumour cell ant... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22514 Sat, 08 Apr 2006 06:00:00 +0100 22514 http://www.medworm.com/index.php?rid=22515&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F4%2F1%2F1 We hypothesize that the energy strategy of a cell is a key factor for determining how, or if, the immune system interacts with that cell. Cells have a limited number of metabolic states, in part, depending on the type of fuels the cell consumes. Cellular fuels include glucose (carbohydrates), lipids (fats), and proteins. We propose that the cell's ability to switch to, and efficiently use, fat for fuel confers immune privilege. Additionally, because uncoupling proteins are involved in the fat burning process and reportedly in protection from free radicals, we hypothesize that uncoupling proteins play an important role in immune privilege. Thus, changes in metabolism (caused by oxidative stresses, fuel availability, age, hormones, radiation, or drugs) will dictate and initiate changes in im... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22515 Fri, 17 Mar 2006 07:00:00 +0100 22515 http://www.medworm.com/index.php?rid=22516&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F3%2F1%2F7 Conclusion: These data suggest that mycobacterial IRIS is associated with inadequate immune reconstitution rather than vigorous specific T-cell responses, and concomitant administration of IL-2 and GM-CSF immunotherapy with effective ART may correct/augment T-cell immunity in such setting resulting in clinical benefit. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22516 Sun, 25 Sep 2005 06:00:00 +0100 22516 http://www.medworm.com/index.php?rid=22517&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F3%2F1%2F6 Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the association of arthritis and psoriasis. PsA runs a variable course, from mild synovitis to severe, progressive, erosive arthropathy. The pathogenesis of PsA involves alteration in the components of the immune response, although the exact cause of PsA is unknown. A number of patients with severe peripheral arthritis fail to respond to standard conventional therapy. Advances in biotechnology and in our understanding of the immunopathogenesis of PsA have led to great interest and progress in regards to biologic treatments for PsA. Notable success achieved with recently introduced biologic therapies has paved the way for further research and develpoment of additional therapies that should improve outcomes for ... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22517 Fri, 02 Sep 2005 06:00:00 +0100 22517 http://www.medworm.com/index.php?rid=22518&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F3%2F1%2F5 Conclusion: We conclude that TGIK has anti-tumor activity when administered intratumorally, probably by stimulating lymphocytes to attack tumors. This is similar to the effect of GIK on reducing sepsis in critical care patients. We suggest that when GIK is administered exogenously, it restores immune competence to the critically ill or cancer patient and causes destruction of pathogens or tumors, while endogenous resources are devoted to repair. This implies that hormonal therapy may be useful in treating various other pathologies involving immune suppression, as well as malignancies. We also propose research that could bring resolution of the controversy over mechanism and point the way to new therapeutic strategies for numerous diseases including chronic infections and auto-immune diseas... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22518 Fri, 19 Aug 2005 06:00:00 +0100 22518 http://www.medworm.com/index.php?rid=22519&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F3%2F1%2F4 We report a simple one-step procedure where maturing DC containing apoptotic malignant T cells can be prepared rapidly for potential use in vaccine immunotherapy. Ready access to both the DC and apoptotic cells provided by this system will allow extension to other malignancies through the addition of a variety of apoptotic tumor cells and maturation stimuli. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22519 Tue, 19 Jul 2005 06:00:00 +0100 22519 http://www.medworm.com/index.php?rid=22520&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F3%2F1%2F3 The HIV/AIDS epidemic continues to spread despite more than 20 years of significant research and major advances in its treatment. The introduction of highly active antiretroviral therapy in recent years has significantly improved disease treatment with a dramatic impact in HIV/AIDS associated morbidity and mortality in countries which have access to this therapy. Despite these advances, such therapies are imperfect and other therapeutic modalities, including immune-based therapies, are being actively sought. Potential benefits of immune-based therapies include: 1) the improvement of HIV-specific immunity to enhance control of viral replication, 2) the improvement of other aspects of host immunity in order to prevent or delay the development of opportunistic infections and 3) the potential ... Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22520 Wed, 18 May 2005 06:00:00 +0100 22520 http://www.medworm.com/index.php?rid=22521&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F3%2F1%2F2 Conclusion: These results show that the HPV 6, 11, 16 and 18 L1-VLP vaccine formulated with Merck aluminum adjuvant elicits a robust and durable immune response and holds promise as a vaccine for preventing cervical cancer. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22521 Wed, 20 Apr 2005 06:00:00 +0100 22521 http://www.medworm.com/index.php?rid=22522&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F3%2F1%2F1 Conclusion: Our data suggest that the lyophilized BCG vaccine used for BCG programs at different age groups is equally effective and may confer satisfactory protection against tuberculosis in puberty. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22522 Fri, 01 Apr 2005 07:00:00 +0100 22522 http://www.medworm.com/index.php?rid=22523&cid=s_33178_3_f&fid=33178&url=http%3A%2F%2Fwww.jibtherapies.com%2Fcontent%2F2%2F1%2F9 Conclusions: The results indicate that antigenized antibodies expressing conformationally-constrained TCR peptides are a simple means to induce humoral anti-idiotypic immunity against the TCR and to vaccinate against EAE. The study also suggests the possibility to target idiotypic determinants of TCR borne on pathogenetic T cells to vaccinate against disease. (Source: Journal of Immune Based Therapies and Vaccines) Journal of Immune Based Therapies and Vaccines journals http://www.medworm.com/rss/comments.php?id=22523 Fri, 12 Nov 2004 07:00:00 +0100 22523